Outcome of Dana-Farber Cancer Institute (DFCI) Consortium Protocol 95–01 for Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL).

摘要: DFCI Consortium Protocol 95–01 was designed to minimize therapy-related morbidity for children with newly diagnosed ALL without compromising efficacy. Patients were considered high risk (HR) if they met any of the following criteria: 1) white blood cell count (WBC) ≥ 50,000/microliter, 2) age between